News - pharmaLevers

Go to content

News

News & Downloads
  • Cell & Gene Therapy - Budget Impact:Newsletter

  • Cell & Gene Therapy - in a Nutshell: get insights from youtube video (2 min)

  • Affordability - a new decade in health care: get insights from youtube video (8 min)

  • Swiss Payer Study, Aug 2020:
    Proposed solutions for the handling of cost-intensive medicines
    Are the applied pricing models and managed entry agreements (MEAs) for the 20 highest-selling medicines of 2019 sustainable and effective for the healthcare sector? What further optimizations would be appropriate to dampen the cost development? A narrative, solution-oriented approach from a cost object perspective.
    Client: This study was commissioned by curafutura – The Innovative Health Insurers (click here for pdf)


  • Newsletter Nr.8, Feb 2019: Precision Medicine - the concept & reimbursement
    (* sign up below to receive newsletter)

  • Newsletter Nr.7, Sept 2017: Multi Option Reimbursement - Total Value Pricing
    (* sign up below to receive newsletter)

  • Brochure: Re-Evaluation - a continuos life cycle endeavor (Swiss Triennial Revison)
    (* sign up below to receive newsletter)

  • Newsletter Nr.6, Dec 2016: Valueframeworks - what is the impact?
        (* sign up below to receive newsletter)

  • Newsletter Nr.5, June 2016: Disinvestment - good or bad news?  
    (* sign up below to receive newsletter)

  • Budget Impact is the bottle neck: CEA and BIA publications 2005-2015 click here)
  • Country Basket Dynamics (System Dynamics Model click here)
  • Market uptake Continuum (Cause-Effect Relationship Model click here)

  • pharmaLevers has developed  the ISPOR GLOBAL HEALTH CARE SYSTEM ROAD MAP for Switzerland. The Pharmaceutical (click) and Medical Device (click) road maps are no longer available on the ISPOR website - please contact pharmaLevers to get the road maps.


Sign up for Newsletter

pharmaLevers newsletters provide specific information on market access issues in the area of pricing & reimbursement, health economy, HTA and policy for the life science industry, payers and decision makers. The newsletters can also contain information on pharmaLevers offered services in this field.
pharmaLevers is using MailChimp as provider to manage Newsletters.
Please read pharmaLevers privacy policy (section: 2 e-Content Sharing) before subscribing to Newsletters.  

I have read, and I'm agree with the privacy policy (section: 2 e-Content Sharing). I wish to receive pharmaLevers Newsletters:



Back to content